» Articles » PMID: 31863522

Sex- and Age-related Differences in the Management and Outcomes of Chronic Heart Failure: an Analysis of Patients from the ESC HFA EORP Heart Failure Long-Term Registry

Abstract

Aims: This study aimed to assess age- and sex-related differences in management and 1-year risk for all-cause mortality and hospitalization in chronic heart failure (HF) patients.

Methods And Results: Of 16 354 patients included in the European Society of Cardiology Heart Failure Long-Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline-directed medical therapy (GDMT) were high (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P ≤ 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1-year follow-up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all-cause mortality were lower in women than in men (7.1% vs. 8.7%; P = 0.015), as were rates of all-cause hospitalization (21.9% vs. 27.3%; P < 0.001) and there were no differences in causes of death. All-cause mortality and all-cause hospitalization increased with greater age in both sexes. Sex was not an independent predictor of 1-year all-cause mortality (restricted to patients with LVEF ≤45%). Mortality risk was significantly lower in patients of younger age, compared to patients aged >75 years.

Conclusions: There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all-cause mortality in patients with LVEF ≤45%.

Citing Articles

[Clinical characteristics and pharmacological treatment of patients with heart failure in a primary health care cohort].

Giner-Sorian M, Monfa R, Vives R, Fernandez-Garcia S, Vallano A, Morros R Aten Primaria. 2025; 57(7):103205.

PMID: 39823656 PMC: 11787459. DOI: 10.1016/j.aprim.2024.103205.


An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic.

Araujo C, Marco I, Restrepo-Cordoba M, Vila Costa I, Perez-Villacastin J, Goirigolzarri-Artaza J J Clin Med. 2024; 13(23).

PMID: 39685630 PMC: 11642353. DOI: 10.3390/jcm13237171.


Age-Related Outcomes in Heart Failure with Mildly Reduced Ejection Fraction.

Reinhardt M, Schupp T, Behnes M, Lau F, Schmitt A, Abel N J Clin Med. 2024; 13(17).

PMID: 39274363 PMC: 11396372. DOI: 10.3390/jcm13175151.


Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.

Inciardi R, Staal L, Davison B, Lombardi C, Postmus D, Felker M Eur J Heart Fail. 2024; 26(11):2431-2439.

PMID: 39240040 PMC: 11659486. DOI: 10.1002/ejhf.3451.


Characteristics of the phenotypes in prevalent and incident cases of heart failure in primary care: IBERICAN study.

Cinza-Sanjurjo S, Prieto-Diaz M, Pallares-Carratala V, Mico-Perez R, Velilla-Zancada S, Barquilla-Garcia A BMC Prim Care. 2024; 25(1):271.

PMID: 39054420 PMC: 11270967. DOI: 10.1186/s12875-024-02506-1.